Search trials



Primary RegistryProtocol numberPublic titleScientific titleType of studyRecruitment statusLast updated
LBCTR2020043427APD334-302Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative ColitisA Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative ColitisInterventionalComplete08/03/2020
LBCTR2020043428APD334-303An Extension Study for Treatment of Moderately to Severely Active Ulcerative ColitisAn Open-Label Extension Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative ColitisInterventionalPending01/12/2020
LBCTR2019100038asdasdasdsadsd    30/11/2017
LBCTR2018120174BIO-2017-0422Short-Course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-Advanced Rectal AdenocarcinomaShort-Course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal AdenocarcinomaInterventionalRecruiting28/12/2018
LBCTR2020074524BIO-2018-0009Liver diseases in Lebanon Spectrum of Liver diseases in Lebanon: a retrospective cohort studyObservationalComplete17/07/2020
LBCTR2020104612BIO-2019-0257Impact of Phosphorus Ingestion with Fructose and Glucose on Substrate Utilization in Active Individuals During Moderate Exercise Impact of Phosphorus Ingestion with Fructose and Glucose on Substrate Utilization in Active Individuals During Moderate Exercise InterventionalPending08/10/2020
LBCTR2022035012BIO-2021-0404Changes of Resting Metabolic Rate in University AthletesChanges of Resting Metabolic Rate in University AthletesInterventionalPending14/03/2022
LBCTR2020104622BO40336ALINAA PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ALECTINIB VERSUS ADJUVANT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB (TUMORS 4 CM) TO STAGE IIIA ANAPLASTIC LYMPHOMA KINASEPOSITIVE NONSMALL CELL LUNG CANCERInterventionalOther12/10/2020
LBCTR2023115331BO42451A RANDOMIZED DOUBLE-BLIND PHASE IIA STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB AS ADJUNCT TREATMENT IN PREVENTION OF VASO-OCCLUSIVE EPISODES (VOE) IN SICKLE CELL DISEASE (SCD)A RANDOMIZED DOUBLE-BLIND PHASE IIA STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB AS ADJUNCT TREATMENT IN PREVENTION OF VASO-OCCLUSIVE EPISODES (VOE) IN SICKLE CELL DISEASE (SCD)InterventionalRecruiting06/04/2023
LBCTR2019091283C1701-202A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients with Stable Sickle Cell DiseaseA Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients with Stable Sickle Cell DiseaseInterventionalComplete12/09/2019
items per page21 - 30 of 169 items